0000000000591127

AUTHOR

Natalia Chueca

showing 3 related works from this author

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

2021

Background & Aims There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients. Methods Samples from 40 patients with HCV genotypes (GT) 1-4 in whom VOX/VEL/SOF retreatment failed were collected within the European Resistance Study Group. Population-based resistance analyses were conducted and clinical parameters and retreatment efficacies were evaluated retrospectively in 22 patients. Results Most VOX/VEL/SOF failure patients were infected with HCV GT3a (n = 18, 45%) or GT1a (n = 11, 28%) and had cirrhosis …

0301 basic medicineHepatitis C Virusmedicine.medical_specialtySofosbuvirVoxilaprevirPopulationresistance-associated substitutionsDirect-acting antiviralVoxilaprevir/velpatasvir/sofosbuvir.GastroenterologySettore MED/07Telaprevir03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVoxilaprevir/Velpatasvir/SofosbuvirInternal medicineBoceprevirRescue therapymedicineResistance-associated substitutioneducationdirect-acting antiviralsDAAeducation.field_of_studyHepatologybusiness.industryvirus diseasesGlecaprevirDAA; HCV; Hepatitis C Virus; Voxilaprevir/Velpatasvir/Sofosbuvir; direct-acting antivirals; rescue therapy; resistance-associated substitutionsdigestive system diseasesPibrentasvirRegimen030104 developmental biologychemistryHCV030211 gastroenterology & hepatologyHepatitis C virubusinessmedicine.drugJournal of Hepatology
researchProduct

Bacteria associated with periodontal disease are also increased in health.

2020

Background The objective of this cross-sectional clinical study was to analyze the differences in the microbiome in gingival sulci of adult patients in the presence or absence of chronic periodontitis. Material and Methods Patients with or without periodontal disease were included in this cross-sectional study. Subgingival biofilm samples were collected and analyzed by 16S massive pyrosequencing. Functional analyses were also performed. Results A total of 15 phyla, 154 genera and 351 species were detected globally. Differences between disease and non-disease samples were observed in all taxonomical levels which suggest functional profile changes in the community. It was found that the main …

AdultCross-sectional studyGingivaPhysiologyDiseaseTranscriptome03 medical and health sciences0302 clinical medicinemedicineHumansPeriodontologyMicrobiomeGeneral DentistrybiologyBacteriaResearchMicrobiotaBiofilm030206 dentistrymedicine.diseasebiology.organism_classification:CIENCIAS MÉDICAS [UNESCO]Chronic periodontitisCross-Sectional StudiesOtorhinolaryngologyBiofilmsUNESCO::CIENCIAS MÉDICASChronic PeriodontitisPyrosequencingSurgeryBacteria
researchProduct

The Administration of Escherichia coli Nissle 1917 Ameliorates Development of DSS-Induced Colitis in Mice

2018

The beneficial effects of probiotics on immune-based pathologies such as inflammatory bowel disease (IBD) have been well reported. However, their exact mechanisms have not been fully elucidated. Few studies have focused on the impact of probiotics on the composition of the colonic microbiota. The aim of the present study was to correlate the intestinal anti-inflammatory activity of the probiotic Escherichia coli Nissle 1917 (EcN) in the dextran sodium sulfate (DSS) model of mouse colitis with the changes induced in colonic microbiota populations. EcN prevented the DSSinduced colonic damage, as evidenced by lower disease activity index (DAI) values and colonic weight/length ratio, when compa…

intestinal microbiota0301 basic medicineDSS colitisIntestinal microbiotaProbioticmedicine.disease_causeInflammatory bowel diseaselaw.invention03 medical and health sciencesProbioticImmune systemlawmicroRNAmedicinePharmacology (medical)ColitisEscherichia coliOriginal ResearchPharmacologymicroRNAbusiness.industrylcsh:RM1-950PyrosequencingMicroRNAmedicine.diseasepyrosequencinglcsh:Therapeutics. Pharmacology030104 developmental biologyMechanism of actionImmunologymedicine.symptombusinessDysbiosisprobioticFrontiers in Pharmacology
researchProduct